Drug recall · November 13, 2019
Cefdinir for Oral Suspension USP recall
Why: Presence of Foreign substance: identified as a dead ant.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Cefdinir for Oral Suspension USP, 125 mg/5mL, packaged in a) 60 mL bottle (NDC 68180-722-20), b) 100 mL bottle (NDC 68180-722-10), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA
- Lots / codes
Lot #: a) F900153, Exp 11/20; b) F802327, F802328, F802329, Exp 11/20
- Quantity
- a) 4074 bottles b) 30,300 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Product was distributed to major distributors/wholesalers throughout the United States.
- Initiated
- November 1, 2019 · Voluntary: Firm initiated
- Classified
- November 7, 2019
- Reported
- November 13, 2019
- Ended
- March 4, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefdinir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.